FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072500390> ?p ?o ?g. }

• W2072500390 endingPage "329" @default.
• W2072500390 startingPage "323" @default.
• W2072500390 abstract "<h2>Abstract</h2> When misonidRzOle (MISO) was introduced into clinical trials there were great expectations that the cure rate of many tumors would be dramatically increased. The lack of efficacy of MISO discouraged further studies with hypoxic cell sensitizers. In recent years superior sensitizers SR 2508 and RO-03-8799 have been introduced into the clinic. SR 2508 is less neurotoxic than MISO, allowing more than three times the total amount of drug to be administered. Furthermore, based on the analysis of a patient's plasma pharmacokinetic profile, neurotoxicity may be largely avoidable. RO-03-8799 is superior in that it produces a higher sensitizer enhancement ratio than MISO for the same administered dose. Unlike with MISO and SR 2508, the dose of RO-03-8799 that can be administered is limited by acute toxicity with no cumulative toxicity having yet been encountered. The lack of overlapping toxicities of RO-03-8799 and SR 2508 may permit their simultaneous use with radiation thereby further increasing the utility of this class of compounds. Study design has improved and the expected clinical benefit from sensitizers has been clarified. Sensitizers, like particle radiation therapy and hyperthermia will, if successful, effect the rate of local tumor control, but cannot improve the cure rate of patients with preexisting metastatic disease. Taking into account the need to optimize reoxygenation, the various reasons for tumor radioresistance other than hypoxia, and the lower oxygen and sensitizer enhancement ratios at 200 cGy per fraction, it is likely that sensitizers will provide some clinical benefit for patients with selected tumor types. Future trials with sensitizers may not only provide clinical benefit but may help answer the question as to the role of hypoxia in clinical radiotherapy." @default.
• W2072500390 created "2016-06-24" @default.
• W2072500390 creator A5059202876 @default.
• W2072500390 date "1985-02-01" @default.
• W2072500390 modified "2023-10-16" @default.
• W2072500390 title "Hypoxic cell radiosensitizers: Expectations and progress in drug development" @default.
• W2072500390 cites W167451947 @default.
• W2072500390 cites W1965636506 @default.
• W2072500390 cites W1969082094 @default.
• W2072500390 cites W1971141762 @default.
• W2072500390 cites W1978684582 @default.
• W2072500390 cites W1984316741 @default.
• W2072500390 cites W1994216439 @default.
• W2072500390 cites W1996055650 @default.
• W2072500390 cites W1997961850 @default.
• W2072500390 cites W2016262033 @default.
• W2072500390 cites W2017109171 @default.
• W2072500390 cites W2017116002 @default.
• W2072500390 cites W2020982398 @default.
• W2072500390 cites W2041326882 @default.
• W2072500390 cites W2045862460 @default.
• W2072500390 cites W2055522497 @default.
• W2072500390 cites W2058180816 @default.
• W2072500390 cites W2067835678 @default.
• W2072500390 cites W2071015671 @default.
• W2072500390 cites W2079854430 @default.
• W2072500390 cites W2091142498 @default.
• W2072500390 cites W2093312368 @default.
• W2072500390 cites W2102058191 @default.
• W2072500390 cites W2107488680 @default.
• W2072500390 cites W2114081348 @default.
• W2072500390 cites W2123495555 @default.
• W2072500390 cites W2137189026 @default.
• W2072500390 cites W2140585471 @default.
• W2072500390 cites W2142210429 @default.
• W2072500390 cites W2142569142 @default.
• W2072500390 cites W2319463151 @default.
• W2072500390 cites W2394901835 @default.
• W2072500390 cites W2419530072 @default.
• W2072500390 cites W2078486205 @default.
• W2072500390 doi "https://doi.org/10.1016/0360-3016(85)90154-3" @default.
• W2072500390 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3156109" @default.
• W2072500390 hasPublicationYear "1985" @default.
• W2072500390 type Work @default.
• W2072500390 sameAs 2072500390 @default.
• W2072500390 citedByCount "59" @default.
• W2072500390 countsByYear W20725003902014 @default.
• W2072500390 countsByYear W20725003902016 @default.
• W2072500390 countsByYear W20725003902019 @default.
• W2072500390 countsByYear W20725003902020 @default.
• W2072500390 countsByYear W20725003902021 @default.
• W2072500390 countsByYear W20725003902022 @default.
• W2072500390 crossrefType "journal-article" @default.
• W2072500390 hasAuthorship W2072500390A5059202876 @default.
• W2072500390 hasConcept C112705442 @default.
• W2072500390 hasConcept C126322002 @default.
• W2072500390 hasConcept C143998085 @default.
• W2072500390 hasConcept C178790620 @default.
• W2072500390 hasConcept C185592680 @default.
• W2072500390 hasConcept C202751555 @default.
• W2072500390 hasConcept C2779949491 @default.
• W2072500390 hasConcept C2780035454 @default.
• W2072500390 hasConcept C2781305896 @default.
• W2072500390 hasConcept C29730261 @default.
• W2072500390 hasConcept C509974204 @default.
• W2072500390 hasConcept C540031477 @default.
• W2072500390 hasConcept C55493867 @default.
• W2072500390 hasConcept C58962609 @default.
• W2072500390 hasConcept C71924100 @default.
• W2072500390 hasConcept C7836513 @default.
• W2072500390 hasConcept C98274493 @default.
• W2072500390 hasConceptScore W2072500390C112705442 @default.
• W2072500390 hasConceptScore W2072500390C126322002 @default.
• W2072500390 hasConceptScore W2072500390C143998085 @default.
• W2072500390 hasConceptScore W2072500390C178790620 @default.
• W2072500390 hasConceptScore W2072500390C185592680 @default.
• W2072500390 hasConceptScore W2072500390C202751555 @default.
• W2072500390 hasConceptScore W2072500390C2779949491 @default.
• W2072500390 hasConceptScore W2072500390C2780035454 @default.
• W2072500390 hasConceptScore W2072500390C2781305896 @default.
• W2072500390 hasConceptScore W2072500390C29730261 @default.
• W2072500390 hasConceptScore W2072500390C509974204 @default.
• W2072500390 hasConceptScore W2072500390C540031477 @default.
• W2072500390 hasConceptScore W2072500390C55493867 @default.
• W2072500390 hasConceptScore W2072500390C58962609 @default.
• W2072500390 hasConceptScore W2072500390C71924100 @default.
• W2072500390 hasConceptScore W2072500390C7836513 @default.
• W2072500390 hasConceptScore W2072500390C98274493 @default.
• W2072500390 hasIssue "2" @default.
• W2072500390 hasLocation W20725003901 @default.
• W2072500390 hasLocation W20725003902 @default.
• W2072500390 hasOpenAccess W2072500390 @default.
• W2072500390 hasPrimaryLocation W20725003901 @default.
• W2072500390 hasRelatedWork W1969876219 @default.
• W2072500390 hasRelatedWork W2034798313 @default.
• W2072500390 hasRelatedWork W2049819497 @default.
• W2072500390 hasRelatedWork W2071751316 @default.
• W2072500390 hasRelatedWork W2153137055 @default.

• next